Covishield booster dose cannot be recommended without clinical trials: CDSCO panel
Amid the emergence of the new Covid variant Omicron, the SII had sought approval to administer the booster dose of its Covishield vaccine on the basis of adequate stock of the jab and rising demand for the booster shots.;
Advertisement
New Delhi: The Subject Expert Committee (SEC) under Central Drugs Standard Control Organization (CDSCO) has said that Covid-19 booster doses cannot be recommended without clinical trials.
The SEC was reviewing the application of the Serum Institute of India (SII) for the booster dose in a meeting that took place on Friday.
The panel has sought additional data from the SII before another meeting.
Amid the emergence of the new Covid-19 variant Omicron, the SII had sought approval to administer the booster dose of its Covishield vaccine on the basis of adequate stock of the jab and rising demand for the booster shots.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.